Does Adjuvant Nutritional Support Diminish Steroid Dependency in Crohn Disease?

References

• Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn Disease Study. Results of drug treatment. Gastroenterology 1979;77:847–69.
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, et al. European Co-operative Crohn Disease Study (ECCDS). Results of drug treatment. Gastroenterology 1984;88:249–66.
   Google Scholar
• Bringola C, De Simone G, Belloli C, Iannine P, Belluzzi A, Gionchetti P, et al. Steroid treatment in active Crohn disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994;8:465–8.
   PubMed Web of Science ®Google Scholar
• O’Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn disease: a controlled trial. BMJ 1984;288:1859–62.
   Google Scholar
• Giaffer MH, North G, Holdsworth CD. Controlled trial of elemental versus polymeric diet in treatment of active Crohn disease. Lancet 1990;1:816–9.
   Google Scholar
• Verma S, Brown S, Kirkwood B, Giaffer MH. Randomised double-blind trial of polymeric versus elemental diets in treatment of active Crohn disease. Am J Gastroenterol 2000;95: 586–9.
   Web of Science ®Google Scholar
• Gonzalez-Huix F, de Leon R, Fernandez-Banares F, Esteve M, Cabre E, et al. Polymeric enteral diets as primary treatment of active Crohn disease: a prospective steroid controlled trial. Gut 1993;34:778–82.
   Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Metaanalysis of enteral nutrition as a primary treatment of Crohn disease. Gastroenterology 1995;108:1056–67.
   PubMed Web of Science ®Google Scholar
• Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, et al. Initial response and subsequent course of Crohn disease treated with elemental diet or prednisolone. Gut 1993; 34:1198–202.
   Google Scholar
• Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diet in Crohn disease. Aliment Pharmacol Ther 1991;5:115–25.
   PubMed Web of Science ®Google Scholar
• Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten-year experience with an elemental diet in the management of Crohn disease. Gut 1990;31:1133–7.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Gasche C, Wyatt J, Moser G, Lochs H, Vogelsang H, et al. Steroid dependency in Crohn disease [letter]. Lancet 1995;345:859.
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz, Davidson M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn disease. Gut 1994;35:360–2.
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB. Treatment of Crohn disease with 6 mercaptopurine. A long-term randomised double-blind study. N Engl J Med 1980;302: 981–7.
   Google Scholar
• Connell WR, Kamm MA, Ritchie JK, Leonard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34: 1081–5.
   Google Scholar
• Thomson BR, Farbier G, et al. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn disease. The international mesalazine study group. Aliment Pharmacol Ther 1990;4:55–64.
   PubMed Web of Science ®Google Scholar
• Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn disease: A multicenter placebo-controlled study. Gastroenterology 1993;104:435–9.
   PubMed Web of Science ®Google Scholar
• Thomson ABR, Wright JP, Vatn M, et al. Mesalazine (Mesalal / Claversal) 1.5 g b.d. vs placebo in the maintenance of remission of patients with Crohn disease. Aliment Pharmacol Ther 1995;9: 673–83).
   Google Scholar
• Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. and the groupe d’etudes therapeutiques des affections inflammatories digestives. Mesalamine in Crohn disease with steroid induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110:688–93.
   Google Scholar
• O’Brien CJ, Giaffer MH, Cann PA, Holdsworth CD. Elemental diet in steroid dependent and steroid refractory Crohn’s disease. Am J Gastroenterol 1991;86:1614–8.
   PubMed Web of Science ®Google Scholar
• Harries AD, Danis V, Heatley RV, Jones LA, Fifield R, Newcombe RG. Controlled trial of supplemented oral nutrition in Crohn disease. Lancet 1983;1:887–90.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn disease activity index. National Co-operative Crohn disease study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Smith R. Corticosteroids and osteoporosis. Thorax 1990;45: 573–8.
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Boisseau VC, Avioli LV. Effects of chronic costicosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 1974;39:274–82.
   Google Scholar
• Compton JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410–15.
   PubMed Web of Science ®Google Scholar
• Piggott F, Roux C, Chausade S, Hardelin D, Pelleter O, Montburn TDP. Low bone density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396–403.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, MacPherson A, MacKintosh C, Buxton-Thomas M, Frogacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228–33.
   Google Scholar
• Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Osteopenia in inflammatory bowel disease (IBD) is related to prednisolone use and not disease diagnosis: a prospective study. Gastroenterology 1993;105:A541
   Google Scholar
• Belli DC, Seidman E, Bouthiller L, et al. Chronic intermittent elemental diet improves growth in children with Crohn disease. Gastroenterology 1988:94:603–10.
   PubMed Web of Science ®Google Scholar